Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-02-20
2007-02-20
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S178100, C530S387100
Reexamination Certificate
active
09750972
ABSTRACT:
The present invention relates to the use of alpha (2) macroglobulin (“α2M”) receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other molecules that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the α2M receptor, and modulate the interaction of the α2M receptor with its ligand, such as HSPs, and methods for using compositions comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
REFERENCES:
patent: 5112298 (1992-05-01), Prince et al.
patent: 5554293 (1996-09-01), Uhoch
patent: 5637082 (1997-06-01), Pages et al.
patent: 5830464 (1998-11-01), Srivastava et al.
patent: 5837251 (1998-11-01), Srivastava
patent: 5846928 (1998-12-01), Kishida
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5968526 (1999-10-01), Garman et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava
patent: 6027731 (2000-02-01), Pauza
patent: 6033561 (2000-03-01), Schoendorfer
patent: 6156311 (2000-12-01), Strickland et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 2002/0001841 (2002-01-01), Kaltoft et al.
patent: WO 94/14471 (1994-07-01), None
patent: WO 94/14976 (1994-07-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/04794 (1997-02-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 98/46739 (1997-07-01), None
patent: WO 98/42752 (1998-10-01), None
patent: WO 98/46743 (1998-10-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/03003 (2000-01-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 00/38760 (2000-07-01), None
patent: WO 00/46246 (2000-08-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 02/07755 (2002-01-01), None
Gura T Science Nov. 7, 1997; 1041-1042.
Srivastava P (Nature Rev Immunol Mar. 2002; 2(3); 185-94).
Binder et al J Biol Chem May 2001;276(20):17163-17171.
Basu et al. Immunity Mar. 2001;14(3):303-13, see abstract only.
Weiner et al (Nature Dec. 2002;420:879-884).
Singh (Gerontology 1997;43:79-94).
D'Andrea MR (Med. Hypotheses. 2005;64(3):458-463).
Agostoni et al., 1994, “Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.” Circulation. 90(6):2666-70.
Bednar et al., 1997, “Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke.” J. Neurosurg. 86(1):139-42.
Collen et al., 1989, “Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.” Drugs. 38(3):346-88.
Hanover et al., 1986, “Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake”, J. of Biol. Chem. 261(35): 16732-16737.
Hertz et al., 1990, “Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver”, J. of Biol. Chem. 265(34): 21355-21362.
Hey et al., 1988, “Cloning of a novel member of the low-density lipoprotein receptor family”, Gene 216: 103-111.
Horn et al., 1995, “Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library”, J. of Biol. Chem. 270 (20): 11770-11775.
Huang et al., 1996, “The immunodominant major histocompatability complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product”, Proc. Natl. Acad. Sci. USA. 93: 9730-9735.
Hughes et al., 1981, “Characterization of plasma membrane proteins identified by monoclonal antibodies”, J. of Biol./ Chem. 256(2): 664-671.
Isaacs et al., 1988, “Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recongnition site”, J. Biol. Chem. 263(14): 6709-6714.
Katsutani et al., 1992, “Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice.” Fundam Appl Toxicol. 19(4):555-62.
Kim et al., 1998, “A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E”, J. Biochem. 124: 1072-1076.
Kimber et al., 2002, “Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation.” Biochem Cell Biol. 2002;80(1):103-7.
Moestrup et al., 1990, “Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen”, Exper. Cell Res. 190: 195-203.
Opekun et al., 1999, “Novel therapies forHelicobacter pyloriinfection.” Aliment Pharmacol Ther. 13(1):35-42.
Reed et al., 1990, “Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.” Thromb Haemost. 64(2):276-80.
Yamauchi et al., 2000, “Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study.” Mycoses.43(5):197-202.
Zimecki et al., 1998, “Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals.” Arch Immunol Ther Exp (Warsz). 46(4):231-40.
Zimecki et al., 1999, “Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells.” Arch Immunol Ther Exp (Warsz). 47(2):113-8.
Epplen et al. 1997. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol. 41(3):341-52.
Sotgiu et al. 1998. Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study. Acta Neurol Scand. 98(5):314-7.
Tait, BD. 1990. Genetic susceptibility to type I diabetes: a review. J Autoimmun. 3 Suppl 1:3-11.
Wong et al. 1991. Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus on chromosome 11. Clin Exp Immunol. 83(1):69-73.
Bellone et al., 1999, “Cancer Immunotherapy: synthetic and natural peptides in balance,” Immunology Today 20(10): 457-462.
Binder et al., 2001, “Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91 ,” J. Immunol. 166(8):4968-72.
Binder et al., 2002, “Naturally formed artificially reconstituted non-covalent alpha 2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity,” Cancer Immunity 2:16-24.
Binder and Srivastava, 2004, “Essential role of CD91 in re-presentation of gp96-chaperoned peptides,” Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133.
Dermer, 1994, “Another Anniversary for the War on Cancer,” Biotechnology 12:320.
Freshney, 1983, “Culture of Animal Cells, A Manual of Basic Technique,” Alan R. Liss Inc., New York, p. 4.
Gaiger et al., 2000, “Immunity to WT1 in the animal model and in patients with acute myeloid leukemia,” Blood 96(4):1480-1489.
Goto et al., 2002, “The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation,” J. Mol. Neurosci. 19:37-41.
Herz et al., 2001, “LRP: a multifunctional scavenger and signaling receptor,” J. Clin. Invest. 108:779-784.
Herz et al., 1991, “39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor,” J. Biol. C
Binder Robert J.
Srivastava Pramod K.
Jones Day
University of Connecticut Health Center
Yaen Christopher H.
LandOfFree
α (2) macroglobulin receptor as a heat shock protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with α (2) macroglobulin receptor as a heat shock protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and α (2) macroglobulin receptor as a heat shock protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809824